Wound Management Technologies Announces Cytokine Study Presentation at the Tri-Society Annual Conference 2009 in Lisbon, Portugal

Wound Management Technologies Announces Cytokine Study Presentation at the
Tri-Society Annual Conference 2009 in Lisbon, Portugal

FORT WORTH, Texas, Nov. 3 /PRNewswire-FirstCall/ -- Wound Care Innovations,
LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM), announced
today that a clinical study, "Activated Collagen Accelerates Wound Repair and
Modulates Cytokine Production in Whole Blood and PBMC Cultures" was presented
at the Tri-Society Annual Conference 2009 of the Society for Leukocyte
Biology, International Cytokine Society, & International Society for
Interferon and Cytokine Research, Cellular and Cytokine Interactions in Health
and Disease in Lisbon, Portugal, October 18-21, 2009.

The abstract was presented by authors Gregory B. Pott, K. Scott Beard, and
Leland Shapiro, of the Department of Medicine, University of Colorado Denver,
Aurora, Colorado and included data of patients with lower extremity diabetic
ulcers by Matthew Regulski, Wound Care Center of Ocean County, New Jersey.

The study suggests that activated collagen (CellerateRx) alone was a potent
inducer of IL-6 and the neutrophil chemo-attractant, IL-8, which are important
for the acute response to injury and bacterial infection. The study showed
that treatment of diabetic ulcers with activated collagen (CellerateRx) and
standard therapy significantly accelerated wound healing compared to standard
therapy alone. As well, activated collagen (CellerateRx) significantly
increased spontaneous (unstimulated) levels of IL-8, IL-6, and IL-10. These
results suggest that CellerateRx enhances wound healing, and a possible
mechanism involves specific modulation of the cytokine response in
bacteria-containing wounds.

Briefly, this groundbreaking research suggests:

-- Treatment of diabetic ulcers with activated collagen (CellerateRx) and
standard therapy significantly accelerated wound healing compared to
standard therapy alone

-- Activated collagen (CellerateRx) significantly increased spontaneous
(unstimulated) levels of IL-8, IL-6, and IL-10

-- A biphasic activated collagen (CellerateRx) effect on TNF(alpha) and
IL-1(beta) was shown

"This is a very exciting study for us," stated Cathy Bradshaw, President of
Wound Care Innovations. "Dr. Shapiro is a leading authority with worldwide
recognition and has published extensively on this subject. These results
suggest a scientifically rational mode of action which addresses the results
clinicians have seen with CellerateRx."

CellerateRx is FDA cleared for use on acute and chronic wounds which include
but are not limited to pressure ulcers (stages I-IV), traumatic wounds,
diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial
insufficiency, superficial wounds, and 1st and 2nd degree burns.

About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, and regional offices in Ft.
Lauderdale, Florida is a rapidly growing provider of specialty medical
products and advanced biotechnology solutions. The Company is leveraging its
existing technology and infrastructure to develop opportunities within the
International Biotechnology and Genetic Engineering. WNDM also believes it
is positioned to develop its technology in Cancer Treatment. For more
information on the Company please visit www.woundmanagementtechnologies.com or
call our shareholder information department at 1817 820 7080.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of
1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Ronnie Ambrose
President 954-357-0614
954-357-0614

SOURCE Wound Management Technologies, Inc.

Product information, Cathy Bradshaw, President, +1-954-357-0614; or
Shareholder Relations, Ronnie Ambrose, +1-954-357-0614, both of Wound
Management Technologies, Inc.